Publications

Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. Journal for immunotherapy of cancer. 2025. PMID: 40713179

Wesolowski R, Rugo HS, Specht JM, Han H, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40711480

Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Annals of surgical oncology. 2025. PMID: 40705266

Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Annals of surgical oncology. 2025. PMID: 40699532

Richardson PG, O'Donnell EK, O'Gorman P, Leypoldt LB, Laubach J, Gay F, Leleu X, Facon T, Moreau P, Dimopoulos MA, Goldschmidt H, Mai EK, Cavo M, Weisel KC, Berdeja JG, Orlowski RZ, Beksaç M, Perrot A, Mikhael J, Martin T. Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. Expert opinion on investigational drugs. 2025. PMID: 40657944

Riechelmann RP, Torrezan GT, Bergsland E, Raj N, Strosberg J, Moon F, Felismino TC, Knappskog S, Trevizani E, Cingarlini S, Sorbye H. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. Therapeutic advances in medical oncology. 2025. PMID: 40727887

Zeng Q, Flemming L, Chen Y, Mazumder T, Hammerlindl H, Allen GM, Almeida R, Williams JZ, Hernández-López RA, Eyquem J, Ye CJ, Lim WA, Tang Q, Desai TA, Huang X. Programmable microparticles rewire CAR signaling to enable super-physiological expansion of human T cells in vitro. bioRxiv : the preprint server for biology. 2025. PMID: 40777491

Hawes M, Alway J, Chakravarty D, Kushel M, Max W, Xia F, Neyazi N, Vijayaraghavan M. Cigarette smoke-free home adoption attempts among formerly homeless adults living in permanent supportive housing. Drug and alcohol dependence reports. 2025. PMID: 40762021

Lynce F, Liu X, Li B, McRoy L, Chen C, Liu R, Rugo HS. Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods. NPJ breast cancer. 2025. PMID: 40691446

Roy S, Sun Y, Eastham JA, Gleave M, Wallis CJD, Beltran HA, Kishan AU, Jia AY, Zaorsky NG, Nagar H, Garcia JA, Small EJ, Nguyen P, Attard G, McKay RR, Sartor O, Berlin A, Rosenthal SA, Halabi S, Vince R, Ponsky L, Morgan SC, Hannan R, Raben A, Roach M, Michalski JM, Morris MJ, Sandler HM, Spratt DE. Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer. European urology oncology. 2025. PMID: 40683825

Vicini F, Shah C, Mittal K, Weinmann S, Leo M, Mann GB, Warnberg F, Rabinovitch R, Czerniecki B, Meattini I, Khan AJ, Jhawar S, Gerber N, Willey SC, Borgen P, AlHilli Z, Kruse M, Dabbs D, Shivers SC, Daily A, Whitworth P, Alvarado M, Mouabbi JA, Moran M, Rugo H, O'Shaughnessy JA, Bremer T. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Rec International journal of radiation oncology, biology, physics. 2025. PMID: 40685017

Corcoran CJ, Cuthbert BJ, Glanville DG, Terrado M, Valverde Mendez D, Bratton BP, Schemenauer DE, Tokars VL, Martin TG, Rasmussen LW, Madison MC, Maule AF, Shaevitz JW, Tseng BS, Whitelegge JP, Putonti C, Gaggar A, Beach JR, Kirk JA, Mondragón A, Kroken AR, Allen JP, Goulding CW, Ulijasz AT. A glyoxal-specific aldehyde signaling axis in Pseudomonas aeruginosa that influences quorum sensing and infection. Nature communications. 2025. PMID: 40681494

Minichiello V, Ring M, Adler SR, Bora S, Chiasson AM, Garber TS, Dhruva A, Hu K, Kogan M, Kohatsu W, Dog TL, Mehta DH, Rindfleisch A, Schneiderhan J, Soriano S. Reimagining integrative medicine fellowship core competencies with a health equity lens. The American journal of medicine. 2025. PMID: 40681011

Schinke C, Touzeau C, Oriol A, Mateos MV, Stevens D, Rasche L, Qin X, Kato K, Bathija S, Katz EG, Gries KS, Campagna M, Masterson T, Hilder BW, Tolbert J, Renaud T, Heuck C, Tomlinson C, Moreau P, San-Miguel J, Rodríguez-Otero P, Chari A. Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study. Cancer. 2025. PMID: 40631904

Brooks TR, Zabor EC, Bedelu Y, Yang X, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A, Hernandez-Ilizaliturri FJ, Chinyengetere F, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025. PMID: 40663785

Hertz DL, Venook AP. Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing. JCO precision oncology. 2025. PMID: 40638877

LeVee A, Deutsh A, Lindgren ES, Yan R, Moore H, Pasricha ND, Leventhal J, Dent S, Rugo HS. New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 40632949

Zhang Y, Lev-Ari S, Zaemes J, Della Pia A, DeAgresta B, Gupta S, Marki A, Zemel R, Ip A, Alaoui A, Charalampous C, Rahman I, Wilkins O, Madhavan S, McGarvey P, Pascual L, Atkins MB, Shah NJ. Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictions. JAMIA open. 2025. PMID: 40636413

Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Couselo EM, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai KK, Lebbé C, Gaudy-Marqueste C, Middleton MR, Skolariki A, Samson A, Chesney JA, VanderWalde AM, Zakharia Y, Harrington KJ, Appleton E, Bommareddy PK, Zhu J, Viana M, Hou JW, Coffin RS, Robert C. RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40627813

Kumaraswamy A, Hu YM, Yates JA, Zhang C, Rodansky E, Khokhani D, Flores D, Duan Z, Zhang Y, Tabatabaei S, Slottke R, Ye S, Lara P, Foye A, Ryan CJ, Quigley DA, Huang J, Aggarwal R, Reiter RE, Wicha MS, Beer TM, Rettig M, Gleave M, Evans CP, Witte ON, Stuart JM, Thomas GV, Feng FY, Small EJ, Xia Z, Alumkal JJ. Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer. NPJ precision oncology. 2025. PMID: 40624104